Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 2/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20556374 | 0.97 | SYK (0.63) | SYKMAPTHTTKLK7KLK5 | |
| SCHEMBL20556328 | 0.97 | SYK (0.63) | SYKMAPTHTTKLK7KLK5 | |
| SCHEMBL19345775 | 0.97 | SYK (0.63) | SYKMAPTHTTKLK7KLK5 | |
| SCHEMBL1024150 | 0.96 | MAPT (0.62) | SYKMAPTHTTKLK7KLK5 | |
| SCHEMBL16279057 | 0.96 | MAPT (0.62) | SYKMAPTHTTKLK7KLK5 | |
| SCHEMBL1022899 | 0.93 | SYK (0.67) | SYKMAPTHTTKLK7KLK5 | |
| SCHEMBL20556459 | 0.93 | SYK (0.67) | SYKMAPTHTTKLK7KLK5 | |
| SCHEMBL1022850 | 0.93 | MAPT (0.66) | SYKMAPTHTTKLK7KLK5 | |
| SCHEMBL14447799 | 0.92 | SYK (0.62) | SYKMAPTHTTKLK7KLK5 | |
| SCHEMBL23161521 | 0.90 | SYK (0.65) | SYKMAPTHTTKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697400-B1 | BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES | AICURIS GMBH & CO KG (DE) | 2011-05-25 | — | — | EP | disclosed |
| EP-1797110-B1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7655643-B2 | Antibacterial macrocycles with substituted biphenyl | AICURIS GMBH & CO. KG (DE) | 2010-02-02 | — | — | US | disclosed |
| US-20080275018-A1 | ANTIBACTERIAL AMIDE-MACROCYCLES V | AICURIS GMBH & CO. KG (DE) | 2008-11-06 | — | — | US | disclosed |
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
| EP-1797110-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AiCuris GmbH & Co. KG (DE) | 2007-06-20 | — | — | EP | disclosed |
| US-20070099885-A1 | Antibacterial macrocycles with substituted biphenyl | AICURIS GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | disclosed |
| EP-1697400-A1 | BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES | AiCuris GmbH & Co. KG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2006034786-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO.KG (DE) | 2006-04-06 | — | — | WO | disclosed |
| US-20050256037-A1 | Antibacterial amide macrocyles | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005058943-A1 | BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES | AICURIS GMBH & CO. KG (DE) | 2005-06-30 | — | — | WO | disclosed |
| EP-1117652-B1 | TAN-1057 DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-05-26 | — | — | EP | disclosed |
| US-6617332-B1 | Cyclic amidinourea derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-09-09 | — | — | US | disclosed |
| EP-1117652-A1 | TAN-1057 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000012484-A1 | TAN-1057 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | SYK 3060/4885MAPT 4356/4885HTT 1796/4885 |
| US-20070099885-A1 | Antibacterial macrocycles with substituted biphenyl | NOD2, AHR, BCL2 | SYK 2241/4885MAPT 4258/4885HTT 706/4885 |
| US-20050256037-A1 | Antibacterial amide macrocyles | AADAC, PAM, NOD2 | SYK 3666/4885MAPT 4168/4885HTT 907/4885 |
| US-20080275018-A1 | ANTIBACTERIAL AMIDE-MACROCYCLES V | ARG1, HRH3, H1-0 | SYK 2058/4885MAPT 4840/4885HTT 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.